Inhibition of bystander cell proliferation
| BVDU | |||||
|---|---|---|---|---|---|
| 10 μM | 1 μM | 0.1 μM | 0.01 μM | 0.001 μM | |
| % | |||||
| ost−/ost+(90/10) | −49 ± 3 | −35 ± 11 | −33 ± 13 | 2 ± 4 | 3 ± 6 |
| ost−/ost+(90/10) + HU | −46 ± 9 | −60 ± 13 | −44 ± 12 | −36 ± 7 | −21 ± 4 |
| ost−/ost+(75/25) | −38 ± 9 | −36 ± 10 | −26 ± 5 | −6 ± 4 | 1 ± 4 |
| ost−/ost+(75/25) + HU | −46 ± 5 | −44 ± 16 | −41 ± 19 | −35 ± 7 | −21 ± 11 |
| ost−/ost+(50/50) | −43 ± 5 | −35 ± 6 | −11 ± 7 | −3 ± 9 | 3 ± 7 |
| ost−/ost+(50/50) + HU | −38 ± 1 | −34 ± 9 | −34 ± 9 | −33 ± 8 | 3 ± 6 |
| ost−/ost+(25/75) | −26 ± 2 | −23 ± 3 | −9 ± 3 | −5 ± 4 | 1 ± 6 |
| ost−/ost+(25/75) + HU | −21 ± 1 | −22 ± 7 | −19 ± 2 | −34 ± 14 | −19 ± 12 |
The numbers shown are the calculated relative inhibition of bystander cell proliferation (average ± S.D.) compared with control cells as described under Materials and Methods. ost−/ost+, ratio of untransfected osteosarcoma cells (ost−) and Dm-dNK expressing osteosarcoma cells (ost+).
HU, hydroxyurea.